港股异动 | 君实生物(01877)再涨超6% 特瑞普利单抗获FDA批准上市 在美定价约8900美元
君实生物(01877)再涨超6%，截至发稿，涨5.72%，报23.1港元，成交额2384.12万港元。
消息面上，10月27日，君实生物合作伙伴Coherus收到FDA通知，特瑞普利单抗BLA已获批准。华金证券认为，本次特瑞普利单抗获FDA批准上市，意味着中国国产PD-1单抗在临床试验设计、临床试验完整性等方面得到FDA认可，具有里程碑意义。
值得注意的是，Coherus发布公告，LOQTORZI(toripalimab，特瑞普利单抗)在美销售价格为每瓶8892.03美元。这一定价约合人民币63604.69元，为其国内定价的30多倍。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.